Journal Mobile Options
Table of Contents
Vol. 18, No. 2, 2004
Issue release date: August 2004
Dement Geriatr Cogn Disord 2004;18:227–232

Specific Functional Effects of Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease

Doody R. · Wirth Y. · Schmitt F. · Möbius H.J.
Departments of aNeurology, Baylor College of Medicine, Houston, Tex., and bNeurology and Psychiatry, University of Kentucky, Lexington, Ky., USA; cMerz Pharmaceuticals GmbH, Frankfurt, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Treatment of Alzheimer’s disease (AD) that combats progressive functional deterioration can improve the patient’s quality of life and reduce caregiver burden. Memantine, a moderate affinity N-methyl-D-aspartate receptor antagonist, reduces global deterioration in AD patients and provides cognitive and functional benefits relative to placebo. Two previous studies reported statistically significant benefits of memantine for overall functional ability on the Alzheimer Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADL19), Functional Assessment Staging, and G2 scale. The present study reports a single-item analysis of the ADL scales from the two trials and shows that patients treated with memantine demonstrated a numerical advantage over placebo on all items assessed. These results help to translate the positive effects of memantine into specific aspects of functional ability, information that is relevant to AD patients and their families as well as to researchers interested in the assessment of functional ability in AD clinical trials.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Winblad B, Poritis N: Memantine in severe dementia: Results of the M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135–146.
  2. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ: Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348:1333–1341.
  3. Lipton SA, Rosenberg PA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613–622.
  4. Danysz W, Parsons CG: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: Preclinical evidence. J Geriatr Psychiatry Neurol 2003;18:S23–S32.
  5. Parsons CG, Quack G, Bresink I, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W: Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonist in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995;34:1239–1258.
  6. Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ: Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics 2003;21:327–340.
  7. Winblad B, Möbius HJ, Stöffler A: Glutamate receptors as a target for Alzheimer’s disease – Are clinical results supporting the hope? J Neural Transm 2002;62(suppl):217–225.
  8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ANDRA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  9. American Psychiatric Association: DSM-III-R organic mental syndromes and disorders; in: DSM-III-R Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, American Psychiatric Association, 1987, pp 103–123.
  10. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33–S39.

    External Resources

  11. Van der Kam P, Hoeksma BH: The usefulness of BOP and SIVIS (ADL and behavior rating scales) for the estimation of workload in a psychogeriatric nursing home: Results of a time-standard study. Tijdschr Gerontol Geriatr 1989;20:159–166.
  12. Van der Kam P, Mol F, Wimmers MFH: Beoordelingsschall voor oudere patienten (BOP). Deventer, Van Loghum Slaterus, 1971.
  13. Ferm L: Behavioural activities in demented geriatric patients. Gerontol Clin (Basel) 1974;16:185–194.
  14. Arnold K, Lehfeld H, Mösler T, Erzigkeit H: Scale properties of the D-scale in severe dementia (abstract). Neurobiol Aging 1998;19(suppl 4S):30.
  15. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001;57:613–620.
  16. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P, The Donepezil MSAD Study Investigators Group: Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51:737–744.
  17. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004;291:317–324.
  18. Hartmann S, Möbius HJ: Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003;18:81–85.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50